Biomarkers Landmark-class

Computational Pathology Promises Automation but Faces Major Adoption Hurdles

This review maps the current landscape of AI-driven computational pathology, from automating routine diagnostic tasks to discovering novel prognostic and predictive biomarkers directly from tissue morphology. Despite rapid innovation, clinical integration remains limited by operational, regulatory, ethical, and financial barriers that the pathology community must address.

The original study

Computational pathology in cancer diagnosis, prognosis, and prediction - present day and prospects.

Authors
Verghese G, Lennerz JK, Ruta D, Ng W, Thavaraj S, Siziopikou KP, et al.
Journal
The Journal of pathology
Type
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PMID
37580849
Read the original study →

Original abstract

Computational pathology refers to applying deep learning techniques and algorithms to analyse and interpret histopathology images. Advances in artificial intelligence (AI) have led to an explosion in innovation in computational pathology, ranging from the prospect of automation of routine diagnostic tasks to the discovery of new prognostic and predictive biomarkers from tissue morphology. Despite the promising potential of computational pathology, its integration in clinical settings has been limited by a range of obstacles including operational, technical, regulatory, ethical, financial, and cultural challenges. Here, we focus on the pathologists' perspective of computational pathology: we map its current translational research landscape, evaluate its clinical utility, and address the more common challenges slowing clinical adoption and implementation. We conclude by describing contemporary approaches to drive forward these techniques. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.